Solbinsiran injections to lower very high triglycerides

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 study enrolls adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL confirmed on two separate screening visits) and a BMI of 18.5–45 kg/m2 to receive two subcutaneous injections of solbinsiran or placebo. The trial compares changes in triglycerides and other lipid measures versus placebo while closely monitoring safety. Key exclusions include recent major atherosclerotic cardiovascular events, genetically confirmed familial chylomicronemia syndrome, prior or planned gene therapy, and recent chronic alcohol abuse. The study is sponsored by Eli Lilly and conducted at multiple U.S. clinical research sites.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* History of fasting triglyceride levels of ≥500 milligrams per deciliter (mg/dL), based on medical history
* Fasting triglyceride level ≥500 mg/dL at two separate visits during screening (at least 7 days apart)
* Have a body mass index (BMI) within the range of 18.5 to 45.0 kilograms per square meter (kg/m2) (inclusive)

Exclusion Criteria:

* Have had a major atherosclerotic cardiovascular event within the past 3 months prior to screening
* Have a known genetically confirmed diagnosis of Familial Chylomicronemia Syndrome
* Have a history of or planned treatment involving any gene editing or gene therapy modalities, including but not limited to CRISPR-based, viral vector-mediated, or other genetic modification techniques
* Have a history of chronic alcohol abuse within 3 years prior to screening

Where it's running

• Ecogene-21
  Chicoutimi, Canada Recruiting
• C.I.C. Mauricie inc.
  Trois-Rivières, Canada Recruiting
• ARC Biosystems
  Vancouver, Canada Recruiting
• Peking University Third Hospital
  Beijing, China Recruiting
• The First Affiliated Hospital of Henan University of Science &Technology
  Luoyang, China Recruiting
• The Affiliated Hospital of Xuzhou Medical College
  Xuzhou, China Recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ion775 for high triglyceride levels: safety, tolerability, and how well it works

  A drug called ION775 is being tested to see if it can safely lower fasting triglycerides in adults with hypertriglyceridemia or severe hypertriglyceridemia who are already on standard lipid medicines.

  Recruiting at 17 sites Phase 2 Ionis Pharmaceuticals, Inc. · Lincoln, California and 17 other locations · NCT07604974

• Plozasiran for adults with severe high triglycerides at risk of acute pancreatitis

  This trial will test whether plozasiran injections every three months can lower triglycerides and reduce pancreatitis risk in adults with severe high triglycerides who have had multiple recent pancreatitis attacks.

  Recruiting at 139 sites Phase 3 Arrowhead Pharmaceuticals · Los Angeles, California and 139 other locations · NCT06880770

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Abemaciclib in healthy adults: comparing tablet and granule forms to see how they enter the bloodstream

  This study tests different oral forms of abemaciclib in healthy volunteers to see how much and how fast the drug gets into the blood and what side effects occur.

  Recruiting Phase 1 Eli Lilly and Company · Singapore · NCT07818967

• Weekly tirzepatide vs placebo for pediatric obesity (6 to <12 years)

  This study tests whether weekly tirzepatide can help children aged 6 to under 12 with obesity, in addition to healthy lifestyle guidance.

  Recruiting at 2 sites Phase 3 Eli Lilly and Company · Tucson, Arizona and 81 other locations · NCT07817875

• Testing LY4329090 in adults with overweight or obesity who are otherwise healthy

  This study tests how LY4329090 works in adults with overweight or obesity who are otherwise healthy to see if it is tolerated and what side effects might occur.

  Recruiting at 2 sites Phase 1 Eli Lilly and Company · Daytona Beach, Florida and 2 other locations · NCT07808073

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.